Study of Aripiprazole in Patients With Acute Bipolar Mania

PHASE3CompletedINTERVENTIONAL
Enrollment

615

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Bipolar Disorder
Interventions
DRUG

Placebo

Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).

DRUG

Aripiprazole

Tablets, oral, 15-30 mg, once daily, 12 weeks.

DRUG

Haloperidol

Capsule, oral, 5-15 mg, once daily, 12 weeks.

Trial Locations (45)

Unknown

Local Institution, Anaheim

Local Institution, Cerritos

Local Institution, Garden Grove

Local Institution, National City

Local Institution, Pico Rivera

Local Institution, Riverside

Local Institution, San Diego

Local Institution, Washington D.C.

Local Institution, Maitland

Local Institution, Tampa

Local Institution, Shreveport

Local Institution, Albuquerque

Local Institution, Cleveland

Local Institution, Oklahoma City

Local Institution, DeSoto

Local Institution, Burgas

Local Institution, Novi Iskar

Local Institution, Pleven

Local Institution, Sofia

Local Institution, Varna

Local Institution, Osijek

Local Institution, Rijeka

Local Institution, Split

Local Institution, Zagreb

Local Institution, Zapopan

Local Institution, Mexico City

Local Institution, Col. Obispado

Local Institution, Monterrey

Local Institution, Fracc. Industrias

Local Institution, Mérida

Local Institution, Nuevo León

Local Institution, Lima

Local Institution, Lipetsk

Local Institution, Arkhangelsk

Local Institution, Kazan'

Local Institution, Leningrad Region

Local Institution, Moscow

Local Institution, Nizhny Novgorod

Local Institution, Saint Petersburg

Local Institution, Samara

Local Institution, Volgograd

Local Institution, Florida

Local Institution, Pretoria

Local Institution, Berea

Local Institution, Durban

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY